Logo

OFIX

Orthofix Medical Inc.

OFIX

Orthofix Medical Inc. • NASDAQ
$16.09 ▼ -0.31% (-0.05)
Market Cap $637.16 M
52w High $20.48
52w Low $10.24
Dividend Yield 0%
P/E -5.31
Volume 92.23K
Outstanding Shares 39.60M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $205.634M ▲ $165.569M ▲ $-22.795M ▼ -11.085% ▼ $-0.57 ▼ $-3.058M ▼
Q2-2025 $203.121M ▲ $155.536M ▼ $-14.081M ▲ -6.932% ▲ $-0.36 ▲ $7.724M ▲
Q1-2025 $193.646M ▼ $170.492M ▲ $-53.094M ▼ -27.418% ▼ $-1.35 ▼ $-11.945M ▼
Q4-2024 $215.657M ▲ $160.318M ▲ $-29.146M ▼ -13.515% ▲ $-0.75 ▼ $12.543M ▲
Q3-2024 $196.606M $153.952M $-27.388M -13.93% $-0.71 $-4.639M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $65.946M ▲ $832.61M ▼ $390.124M ▲ $442.486M ▼
Q2-2025 $65.606M ▲ $837.157M ▲ $378.81M ▲ $458.347M ▲
Q1-2025 $57.953M ▼ $823.144M ▼ $364.85M ▼ $458.294M ▼
Q4-2024 $83.238M ▲ $893.294M ▲ $390.17M ▲ $503.124M ▼
Q3-2024 $30.054M $867.872M $341.948M $525.924M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-22.795M ▼ $12.402M ▲ $-9.894M ▼ $-5.152M ▼ $-2.743M ▼ $2.498M ▼
Q2-2025 $-14.081M ▲ $11.639M ▲ $-7.097M ▼ $2.64M ▲ $8.236M ▲ $4.53M ▲
Q1-2025 $-53.094M ▼ $-18.391M ▼ $-6.736M ▼ $-651K ▼ $-25.285M ▼ $-25.127M ▼
Q4-2024 $-29.146M ▼ $23.73M ▲ $-1.135M ▲ $31.487M ▲ $53.184M ▲ $15.199M ▲
Q3-2024 $-27.388M $11.671M $-5.862M $-2.456M $3.688M $5.859M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Global Orthopedics
Global Orthopedics
 $40.00M ▲$30.00M ▼$30.00M ▲$30.00M ▲
Global Spine
Global Spine
 $180.00M ▲$160.00M ▼$170.00M ▲$170.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has grown steadily over the past several years, with a notable step up after the SeaSpine merger, showing that the combined business is gaining commercial scale. Gross profitability looks reasonably healthy and has improved, suggesting the core products carry attractive economics. At the same time, operating and net results remain in the red, with losses widening around the merger and only modestly improving more recently. Overall, this is a story of better top-line and gross margin performance, but with profitability still under pressure from integration costs, overhead, and continued investment in growth.

Balance Sheet

Balance Sheet The balance sheet expanded significantly with the merger, reflecting a larger asset base and a bigger equity cushion, but has since been nudged down by ongoing losses. Cash levels dipped for several years before recovering more recently, which helps, but liquidity does not appear abundant. Debt has increased meaningfully from earlier years, adding financial leverage and future interest obligations, though it is still balanced by a solid level of equity. The company has room to operate, but persistent losses could gradually erode this flexibility if not addressed.

Cash Flow

Cash Flow Cash generation has been uneven: operating cash flow has swung between positive and negative, only recently turning modestly positive again. Free cash flow has been negative for several years, with a particularly weak period around the merger, though the cash burn now appears to be narrowing. Capital spending is relatively modest and steady, indicating ongoing but not excessive investment in equipment and infrastructure. The key financial question is whether recent improvements in operating performance can translate into consistently positive, self-funding cash flow.

Competitive Edge

Competitive Edge Orthofix holds strong niche positions in areas like bone growth stimulation, limb reconstruction, and specialized spine solutions, and now offers a broad, integrated portfolio across implants, biologics, and surgical navigation. Its distribution network, strengthened by the SeaSpine merger, and deep relationships with surgeons give it meaningful commercial reach and the ability to "bundle" solutions. The company also benefits from a substantial base of clinical evidence, regulatory know-how, and a recognized brand in its focus markets. However, it still competes against much larger medical device players with greater scale, making differentiation, service, and clinical outcomes critical to defending share and pricing power.

Innovation and R&D

Innovation and R&D Innovation is a central part of Orthofix’s strategy, with the 7D FLASH navigation platform standing out as a flagship technology that emphasizes speed, precision, and radiation-free imaging. The company has built a differentiated set of implant and biologic technologies, including advanced surfaces, 3D-printed structures, and a broad allograft and DBM offering supported by a key tissue bank partnership. A steady stream of new product launches in spine and orthopedics, plus earlier-than-expected approvals in areas like bone stimulation, signal an active and productive R&D engine. The trade-off is that this innovation focus requires sustained spending, which weighs on near-term profits while the long-term payoff depends on continued adoption and proven clinical and economic benefits.

Summary

Orthofix has evolved into a larger, more diversified musculoskeletal and spine company with genuine technology differentiation and recognized strengths in bone growth stimulation, navigation, and biologics. Revenue growth and improving gross profitability show that customers are adopting its expanded portfolio, but bottom-line results remain negative and free cash flow has yet to become consistently positive. The balance sheet is still supportive but clearly more leveraged and less cushioned than in the past, putting a premium on execution, cost discipline, and successful integration of the SeaSpine merger. Overall, the company’s potential is closely tied to its ability to convert its strong innovation pipeline and competitive position into durable profitability and reliable cash generation amid intense competitive and regulatory pressures.

NEWS

November 4, 2025 · 7:00 AM UTC

Orthofix Reports Third Quarter 2025 Financial Results

Read more

October 15, 2025 · 7:00 AM UTC

Orthofix to Participate in Upcoming Investor Conferences

Read more

October 14, 2025 · 7:00 AM UTC

Orthofix to Report Third Quarter 2025 Financial Results

Read more

September 4, 2025 · 5:27 PM UTC

ORTHOFIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Orthofix Medical Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Read more